BioStock: Cereno’s CEO on current development and move to First North

Cereno Scientific has three drug candidates in development for the treatment of common and rare cardiovascular diseases. Now, the company is carrying out a rights issue of approximately SEK 110 million to continue advancing all three projects. Additionally, Cereno is pursuing a move to Nasdaq First North Growth Market to increase market awareness and open possibilities with potential investors. To discuss all this and more, BioStock talked to Cereno’s CEO Sten R Sörensen.

Read the interview with Sten R Sörensen at biostock.se:

Cereno’s CEO on current development and move to First North - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/